Home/Maze Therapeutics/Misbah Tahir

MT

Misbah Tahir

Chief Financial Officer

Maze Therapeutics

Therapeutic Areas

Renal Cardiometabolic Metabolic Disorders

Maze Therapeutics Pipeline

Drug	Indication	Phase
MZE829	APOL1-Mediated Kidney Disease (AMKD)	Phase 2
MZE782	Chronic Kidney Disease (CKD) and Phenylketonuria (PKU)	Phase 1/Discovery
Undisclosed GLP-1RA	Obesity	Discovery/Preclinical

Leadership Team at Maze Therapeutics

Chief Executive Officer

Harold Bernstein

President, Research and Development and Chief Medical Officer

Courtney Phillips

General Counsel & Corporate Secretary

Chief Strategy & Business Officer

View full Maze Therapeutics profile